BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31451681)

  • 1. A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study.
    Dumortier J; Duvoux C; Dubel L; Bazin F; Houssel-Debry P
    Ann Transplant; 2019 Aug; 24():506-516. PubMed ID: 31451681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective, Observational Study of Conversion From Immediate- to Prolonged-Release Tacrolimus in Renal Transplant Recipients in France: The OPALE Study.
    Moal V; Grimbert P; Beauvais A; Dubel L; Le Meur Y
    Ann Transplant; 2019 Sep; 24():517-526. PubMed ID: 31477681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to, and patient convenience of, prolonged-release tacrolimus in stable kidney and liver transplant recipients after conversion from immediate-release tacrolimus in routine clinical practice in Switzerland.
    Bonani M; Balaphas A; Bedino G; Bühler L; Dutkowski P; Fausch K; Gluderer S; Graf N; Hirt-Minkowski P; Müllhaupt B; Schönholzer C; Schulz MM; Venzin R; Wüthrich RP
    Swiss Med Wkly; 2021 Feb; 151():w20453. PubMed ID: 33638353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion From Once-Daily Prolonged-Release Tacrolimus to Once-Daily Extended-Release Tacrolimus in Stable Liver Transplant Recipients.
    Altieri M; Delaval G; Kimmoun E; Allaire M; Salamé E; Dumortier J
    Exp Clin Transplant; 2018 Jun; 16(3):321-325. PubMed ID: 28697715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
    Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.
    Comuzzi C; Lorenzin D; Rossetto A; Faraci MG; Nicolini D; Garelli P; Bresadola V; Toniutto P; Soardo G; Baroni GS; Adani GL; Risaliti A; Baccarani U
    Transplant Proc; 2010 May; 42(4):1320-1. PubMed ID: 20534291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients.
    Bäckman L; Persson CA
    Ann Transplant; 2014 Mar; 19():138-44. PubMed ID: 24637379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Conversion From Cyclosporine to Once-Daily Prolonged-Release Tacrolimus in Stable Kidney Transplant Patients: A Multicenter Observational Study in Japan.
    Usuki S; Uno S; Sugamori H; Tanaka H; Aikawa A
    Transplant Proc; 2018 Dec; 50(10):3266-3274. PubMed ID: 30577196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study.
    Melo MJ; Gonçalves J; Guerra JO; Santana A; Nascimento C
    Transplant Proc; 2015 May; 47(4):911-3. PubMed ID: 26036484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.
    Rubik J; Debray D; Kelly D; Iserin F; Webb NJA; Czubkowski P; Vondrak K; Sellier-Leclerc AL; Rivet C; Riva S; Tönshoff B; D'Antiga L; Marks SD; Reding R; Kazeem G; Undre N
    Transpl Int; 2019 Nov; 32(11):1182-1193. PubMed ID: 31325368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature.
    Tran D; Vallée M; Collette S; Senécal L; Lafrance JP; Dandavino R; Boucher A
    Exp Clin Transplant; 2014 Aug; 12(4):323-7. PubMed ID: 24844288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients.
    Wu SW; Tsai HC; Tsai PY; Hung TW; Chang HR; Lian JD
    Swiss Med Wkly; 2013; 143():w13850. PubMed ID: 23986367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.
    Lehner LJ; Reinke P; Hörstrup JH; Rath T; Suwelack B; Krämer BK; Budde K; Banas B
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29052906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients.
    Ruangkanchanasetr P; Sanohdontree N; Supaporn T; Sathavarodom N; Satirapoj B
    Ann Transplant; 2016 Dec; 21():765-774. PubMed ID: 27980321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR; Eckhoff DE; Washburn WK; Teperman LW
    Liver Transpl; 2014 May; 20(5):564-75. PubMed ID: 24493215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
    Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
    Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients.
    Guirado L; Cantarell C; Franco A; Huertas EG; Fructuoso AS; Fernández A; Gentil MA; Rodríguez A; Paul J; Torregrossa JV; Rodríguez A; Alonso A; Hernández D; Burgos D; Jiménez C; Jimeno L; Lauzurica R; Mazuecos A; Osuna A; Plumed JS; Ruiz JC; Zárraga S;
    Am J Transplant; 2011 Sep; 11(9):1965-71. PubMed ID: 21668633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.